InvestorsHub Logo
Followers 33
Posts 1347
Boards Moderated 0
Alias Born 09/29/2019

Re: dtgsanjose post# 97562

Saturday, 04/10/2021 9:37:00 AM

Saturday, April 10, 2021 9:37:00 AM

Post# of 199169
Immunome is a biotech / bio pharmaceutical company that has been mentioned/hashtagged by ENZC exec in two of his recent tweets . He was also quoted in the access wire press release saying that they have found the golden needle in a haystack. Immunome is presenting at an emerging biotech conference, and it’s marketing deck/power point presentation indicates they have found the needle in the haystack. Also, on the same slide/page immunome included an image of a needle in a haystack. ENZC CEO is supposedly presenting on behalf of ENZC and possibly accompanying immunome in the biotech conference to present and discuss findings. If all this is an accurate assessment, then it is likely that immunome will be one of our partners or licensees using ENZC patents to bring a cure for COVID, HIV or both (or additional diseases ENZC patents cover) to market.

Immunome currently trades around $30 per share and has also had some recent leading edge breakthroughs in medicine. I imagine a collaboration to bring a cure to market will significantly drive up the pps for both tickers , all imo. This is not stock advice and I’m not a licensed securities advisor, and this is no way intended to be advice, just my opinion as a shareholder.

I hope this helps! GLTY!